Allegro Bio

Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies

Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint disease, announced today that hydrocelin (ALG-001), its lead injectable microparticle hydrogel, has been...
Boulevard Patience et Beaujonc 3 4000 Liège Belgium